MRK vs QCOM: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Merck & Co., Inc. · Healthcare
$147.17
-4.1% upside to fair value
Med Conviction
Grade C
VS
QUALCOMM Incorporated · Technology
$201.97
-21.1% upside to fair value
Med Conviction
Grade D
High Quality
QuantHub Verdict
MRK has more upside to fair value
(-4.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
QCOM |
| Current Price |
$147.17 |
$201.97 |
| Fair Value Estimate |
$141.07 |
$159.42 |
| Upside to Fair Value |
-4.1%
|
-21.1%
|
| Market Cap |
$363.5B |
$212.1B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
16.5x
|
| Price / Sales |
5.5x
|
4.8x
|
| Price / FCF |
22.6x
|
20.5x
|
| Revenue Growth YoY |
+5.1%
|
-4.0%
|
| Gross Margin |
75.4%
|
54.2%
|
| Operating Margin |
16.7%
|
23.2%
|
| Return on Equity |
6.6%
|
37.3%
|
| Dividend Yield |
2.31% |
1.79% |
| FCF Yield |
4.42%
|
4.88%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely hig…
Qualcomm develops foundational wireless technologies and monetizes them through two main engines: QCT, which supplies Snapdragon application processors and modems, and QTL, which licenses a standards-essential patent portfolio covering CDMA2000, WCDMA, LTE and 5G. The licensing arm and the company's entrenched position in premium Android handsets give it a genuinely high-quality business, evidenc…
Accumulation Zones
| Metric |
MRK |
QCOM |
| Zone Low |
$105.80 |
$119.56 |
| Zone High |
$119.91 |
$135.51 |
| In Buy Zone? |
No
|
No
|